Synonyms: DA-8159 | DA8159 | Zydena®
udenafil is an approved drug (South Korea)
Compound class:
Synthetic organic
Comment: Udenafil (DA-8159) is an oral PDE5 inhibitor that was developed by Dong-A Pharmaceutical Company for erectogenic potential [1,3-4].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Ahn BO, Kang KK, Ahn GJ, Kwon JW, Kim WB, Kang KS, Lee YS. (2003)
Efficacy of DA-8159, a new PDE5 inhibitor, for inducing penile erection in rabbits with acute spinal cord injury. Int J Impot Res, 15 (6): 405-11. [PMID:14671658] |
2. Doh H, Shin CY, Son M, Ko JI, Yoo M, Kim SH, Kim WB. (2002)
Mechanism of erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159. Arch Pharm Res, 25 (6): 873-8. [PMID:12510841] |
3. Oh TY, Kang KK, Ahn BO, Yoo M, Kim WB. (2000)
Erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159. Arch Pharm Res, 23 (5): 471-6. [PMID:11059826] |
4. Shim HJ, Lee EJ, Kim SH, Kim SH, Yoo M, Kwon JW, Kim WB, Lee HS, Lee MG. (2000)
Pharmacokinetics, stability, and blood partition of DA-8159, a new phosphodiesterase V inhibitor. Res Commun Mol Pathol Pharmacol, 108 (3-4): 275-86. [PMID:11913718] |